Skip to main content
Fig. 4 | BMC Cancer

Fig. 4

From: Identification on surrogating overall survival with progression-free survival of first-line immunochemotherapy in advanced esophageal squamous cell carcinoma—an exploration of surrogate endpoint

Fig. 4

PFS-OS correlation at the trial and arm levels. A-B Correlation between the HROS and HRPFS in ITT and PD-L1 + population at trial- level. C-D Relationship between median PFS and median OS in ITT and PD-L1 + population at arm- level. In each comparison, the number of patients is proportional to the size of the circle. Blue shows a weighted linear regression line and green shows its 95% CI. n indicates total number of patients enrolled in RCTs or experimental arms (arms treated with immunochemotherapy). R stands for weighted Pearson correlation coefficient. R2 is the squared correlation coefficients. Abbreviations: CI, confidence interval; HR, hazard ratio; ITT, intent-to-treat; PD-L1 + , programmed death ligand-1 enriched; RCTs, randomized controlled trials; OS, overall survival; PFS, progression-free survival

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us